Accelerating Early-Stage Oncology Global Drug Development:
Connecting West to East
About this webinar
Early-stage oncology development is increasingly global. For emerging biopharma, the goal is not simply to expand into more countries, but to build a development strategy that identifies the right markets, regulatory pathways, sites, investigators and patient populations from the outset.
This webinar brings together oncology drug development experts from Allucent and CMIC to examine how sponsors can strategically incorporate key Western and Asian markets into early-stage oncology programs. The speakers will explore how local expertise and site networks can help sponsors navigate differences between markets and determine where and when each market fits within a global development strategy.
Allucent will examine early oncology development across the US, EU and Canada, including how integrated product development, regulatory, clinical and operational planning can inform critical early decisions and strengthen the path to later-stage development. The discussion will also consider how strategic site selection and established site relationships, including Allucent’s IGNITE Site Network, can support faster study start-up, access to oncology expertise and patient populations and more predictable enrolment.
CMIC will provide an Asia-Pacific perspective, focusing on South Korea and Taiwan and how these markets can contribute to global oncology programs. The discussion will examine regulatory pathways, clinical trial infrastructure, access to leading cancer centers and experienced investigators and practical considerations for site identification, activation and patient recruitment.
Together, Allucent and CMIC will provide a practical view of how product development strategy, regulatory planning, operational expertise and site and patient access can be aligned across North America, Europe and Asia-Pacific. For small and mid-size biopharma, this integrated approach can help focus resources, reduce development risk and accelerate the path to critical oncology milestones.
Register for this webinar to learn how a globally integrated oncology drug development strategy can reduce risk and accelerate progress toward critical development milestones.
Who should attend
- Research and Development (R&D)
- Clinical Project Management/Trial Oversight
- Clinical Operations/Clinical Research
- Medical Affairs/Medical Writing/Pharmacovigilance
- Biostatistics and Data Science
- Regulatory Affairs/Strategy
- Chief Medical Officers (CMOs) and CEOs of small and medium-sized biotech/pharmaceutical companies
- Outsourcing and Procurement
What you will learn
- Building a global strategy early: How to integrate Western and Asian markets into development planning from the outset
- Selecting the right markets: Key considerations including regulatory pathways, oncology expertise, infrastructure and patient access
- Accelerating site and patient access: How established networks and local expertise can support faster start-up and recruitment
- Creating a faster path forward: How early regulatory, clinical and operational decisions can support later-stage development
Featured Speakers
Shinichi Nagase
Shinichi Nagase is an accomplished pharmaceutical industry professional with more than 20 years of experience in clinical development. Throughout his career at global pharmaceutical companies, he has worked with clients and partners worldwide and successfully led multiple development programs in bone metabolism and oncology, including checkpoint inhibitors and CAR-T cell therapies.
Shinichi joined CMIC in 2024, bringing extensive drug development expertise, a global perspective and strategic leadership to drive business growth and strengthen the company’s presence across the Asia-Pacific region. He holds a PhD in Biological Sciences and an MBA and is a registered Pharmacist in Japan.
Ray Reilly
Ray Reilly has more than 30 years of professional experience in clinical development operations. Throughout his career, he has led global clinical operations and monitoring organizations across both biotech and CRO organizations, including BioCryst Pharmaceuticals, Aceragen, TG Therapeutics and IQVIA Biotech.
As Senior Vice President, Global Clinical Operations at Allucent, Ray’s strategic and operational leadership ensures the delivery of high-quality clinical trials through strong execution, regulatory compliance and client partnership. Ray holds a BSc degree in Biology from the University of North Carolina, Chapel Hill.
Partner for this event
Allucent
Allucent is on a mission to help bring new therapies to light by solving the distinct challenges of small and mid-sized biotech companies. The company is purpose-built through the convergence of leading providers to address this unmet need. Today, Allucent is a global provider of comprehensive drug development solutions, including clinical trial operations, regulatory strategy, clinical pharmacology, pharmacovigilance, and biostatistical programming consulting. With more than 30 years of experience in over 70 countries, Allucent’s individualized partnership approach provides experience-driven insights and expertise to assist its clients in successfully navigating the complexities of delivering novel treatments to patients.